首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Dexamethasone for acute asthma exacerbations in children: A meta-analysis
【24h】

Dexamethasone for acute asthma exacerbations in children: A meta-analysis

机译:地塞米松治疗儿童急性哮喘急性发作的荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND OBJECTIVE: Dexamethasone has been proposed as an equivalent therapy to prednisone/prednisolone for acute asthma exacerbations in pediatric patients. Although multiple small trials exist, clear consensus data are lacking. This systematic review and meta-analysis aimed to determine whether intramuscular or oral dexamethasone is equivalent or superior to a 5-day course of oral prednisone or prednisolone. The primary outcome of interest was return visits or hospital readmissions. METHODS: A search of PubMed (Medline) through October 19, 2013, by using the keywords dexamethasone or decadron and asthma or status asthmaticus identified potential studies. Six randomized controlled trials in the emergency department of children ≤18 years of age comparing dexamethasone with prednisone/prednisolone for the treatment of acute asthma exacerbations were included. Data were abstracted by 4 authors and verified by a second author. Two reviewers evaluated study quality independently and interrater agreement was assessed. RESULTS: There was no difference in relative risk (RR) of relapse between the 2 groups at any time point (5 days RR 0.90, 95% confidence interval [CI] 0.46-1.78, Q = 1.86, df = 3, I2 = 0.0%, 10 -14 days RR 1.14, 95% CI 0.77-1.67, Q = 0.84, df = 2, I2 = 0.0%, or 30 days RR 1.20, 95% CI 0.03-56.93). Patients who received dexamethasone were less likely to experience vomiting in either the emergency department (RR 0.29, 95% CI 0.12-0.69, Q = 3.78, df = 3, I2 = 20.7%) or at home (RR 0.32, 95% CI 0.14-0.74, Q = 2.09, df = 2, I2 = 4.2%). CONCLUSIONS: Practitioners should consider single or 2-dose regimens of dexamethasone as a viable alternative to a 5-day course of prednisone/prednisolone.
机译:背景与目的:地塞米松已被提议作为泼尼松/泼尼松龙的等效疗法用于小儿患者的急性哮喘加重。尽管存在多个小型试验,但缺乏明确的共识数据。该系统评价和荟萃分析旨在确定肌内或口服地塞米松是否等同于或优于口服泼尼松或泼尼松龙的5天疗程。感兴趣的主要结果是回诊或再次住院。方法:通过使用地塞米松或地卡龙和哮喘或哮喘状态哮喘的关键词搜索截至2013年10月19日的PubMed(Medline),从而确定了潜在的研究项目。包括六个在18岁以下儿童中进行急诊的随机对照试验,比较了地塞米松和泼尼松/泼尼松龙治疗急性哮喘加重的情况。数据由4位作者提取,并由第二位作者验证。两名评价者独立评估研究质量,并评估了跨族的同意。结果:两组在任何时间点(5天RR 0.90,95%置信区间[CI] 0.46-1.78,Q = 1.86,df = 3,I2 = 0.0)之间的相对复发风险(RR)没有差异。 %,10 -14天RR 1.14、95%CI 0.77-1.67,Q = 0.84,df = 2,I2 = 0.0%或30天RR 1.20、95%CI 0.03-56.93)。接受地塞米松的患者在急诊室(RR 0.29,95%CI 0.12-0.69,Q = 3.78,df = 3,I2 = 20.7%)或在家(RR 0.32,95%CI 0.14)发生呕吐的可能性较小-0.74,Q = 2.09,df = 2,I2 = 4.2%。结论:从业者应考虑地塞米松的单剂或2剂治疗方案,作为强的松/泼尼松龙5天疗程的可行替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号